… Oral afatinib had a manageable tolerability profile. EGFR-mediated adverse … afatinib is a
valuable new option for use in treatment-naïve or EGFR TKI-naïve patients with advanced lung …

… versus chemotherapy as first-line treatment in EGFR-mutant lung cancer LUX-Lung 3
and LUX-Lung 6 evaluated the use of afatinib versus chemotherapy in first-line treatment in …

… Citation3 – Citation8,Citation24,Citation25,Citation30 Skin effects may improve or
completely resolve with continued use of afatinib, although sometimes dose reduction or drug …

… lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib,
regardless of EGFR mutation status (LUX-Lung … to use effective contraception during afatinib …

… However, due to the continued use of afatinib in EGFR mutation–positive patients with
advanced NSCLC, the advanced practitioner will need to be properly trained to educate, prescribe…

… However, these results were derived from controlled studies conducted in selected patients
and are not necessarily representative of real-world use of afatinib. To gain a broader …

… Afatinib also demonstrated activity in mouse xenograft models of either squamous NSCLC …
or lung cancer expressing altered HER2 (mutations/amplifications) [11]. The activity of afatinib …

… in the ongoing studies in patients with EGFR-mutant lung cancer and acquired resistance
to erlotinib or gefitinib. The decision to use afatinib as a frontline treatment for EGFR-mutant …

… use of afatinib in different solid tumors with EGFR or HER2 gene amplifications in the absence
of activating EGFR mutations showed encouraging, albeit limited, activity Citation[40]. In …

… afatinib within a compassionate-use program (CUP). … of action of afatinib on lung cancers
depending on mutant EGFR. It is … afatinib in the German compassionate-use program (CUP) for …